In-Office Dry Eye Treatments: A Comprehensive Guide for 2026

Dry eye disease is a remarkably common condition, affecting millions. For those seeking relief beyond artificial tears, the landscape of in-office treatments has expanded significantly in recent years. Even as the core goal remains addressing meibomian gland dysfunction (MGD) and evaporative dry eye – the primary culprits in most cases – the methods for achieving that have evolved from simple warm compresses and lid scrubs to sophisticated thermal pulsation and light-based therapies. Understanding these options, and what the current evidence supports, is crucial for both clinicians and patients.

For decades, treatment largely consisted of warm compresses and gentle eyelid hygiene with products like Johnson’s baby shampoo. The recognition that biofilm, often containing staph species, contributes to meibomian gland inflammation marked a turning point. Research spearheaded by Hank Perry, MD, highlighted the role of this biofilm, paving the way for more targeted interventions.

BlephEx and the Rise of In-Office Procedures

The first dedicated in-office treatment was arguably BlephEx, invented by James Rynerson, MD. BlephEx employs a handheld instrument and disposable sponges with a specialized cleanser to physically remove biofilm from the lid margins. Often used as a preparatory step before manual gland expression, it aimed to create a cleaner surface for more effective treatment. While Alcon previously licensed and sold BlephEx, its availability may vary.

Okra-Based Exfoliation and Demodex

Another approach gaining traction is Zest (Zocular), a lid margin “shampoo” formulated with okra. This treatment is designed to reduce inflammation and exfoliate the meibomian gland openings, providing rapid relief from itching, irritation, and redness. While widely believed to be effective against Demodex mites, a common contributor to blepharitis and MGD, robust data confirming mite eradication remains limited.

Thermal Pulsation and Expression: LipiFlow and its Competitors

The introduction of thermal pulsation therapy represented a significant leap forward. LipiFlow, developed by TearScience (later acquired by Johnson & Johnson), utilizes disposable activators inserted between the eyelids. These activators deliver controlled heat to the inner lid surface, aiming to liquefy meibum and facilitate gland expression. The concept, largely credited to Donald Korb, OD, incorporates “vectored expression” – massage pressure applied from the base of the glands towards the orifices – designed to maximize gland evacuation. Early studies suggested improvements in contact lens wearing time and overall DED symptoms. Johnson & Johnson acquired LipiFlow in 2017.

LipiFlow’s success spurred the development of competing technologies. ILux (Alcon) combines external heat delivered via LED light with manual expression, offering clinicians direct control over heat placement and pressure. However, treatment quality is highly operator-dependent. ILux also features visualization and photography capabilities of the meibomian glands.

TearCare (Sight Sciences) takes a hybrid approach, using disposable adhesive strips to deliver heat followed by manual expression. The strips are connected to a base unit that sends an electric current to heat the lid skin and underlying glands. Recent research by John A. Hovanesian, MD, FACS, demonstrated TearCare’s effectiveness in reducing symptoms and improving tear breakup time. Sight Sciences has obtained Medicare coverage for TearCare in some regions, though coverage can be variable.

Radiofrequency and the Latest Innovations

The newest entrants in the thermal therapy space utilize radiofrequency (RF) energy applied to the external lid to heat the underlying glands. OptiPLUS (Lumenis) and InMode Forma are examples of this technology. While RF may also improve peri-gland circulation and reduce inflammation, further research is needed to confirm these effects.

The Role of Light Therapy

Intense pulsed light (IPL) therapy has emerged as a powerful tool in DED management, largely thanks to the pioneering function of Rolando Toyos, MD. Initially observed in dermatology patients, IPL’s benefits for dry eye led to its adaptation for ophthalmic use. The Lumenis M22 is a commonly used IPL device, and protocols developed by Dr. Toyos and Laura Periman, MD, are widely adopted.

IPL works on multiple levels. It causes telangiectatic blood vessels on the lid margins to close, reducing inflammation. At a cellular level, it decreases the release of pro-inflammatory cytokines and chemokines. And, invoking biochemical pathways, it enhances adenosine triphosphate (ATP) usage in gland cells. Karl Stonecipher, MD, advocates for low-level light therapy (LLLT) as a cost-effective and low-risk adjunct to IPL, particularly for mild to moderate DED.

Tixel: A Novel Thermo-Mechanical Approach

Tixel (Sentient) represents a truly novel approach, utilizing tiny titanium pyramids to deliver heat therapy just below the skin of the eyelids. This “Thermo-Mechanical Action” melts thickened oil in the meibomian glands and appears to have anti-inflammatory effects. Studies led by Gregg Berdy, MD, have shown Tixel to increase tear breakup time, decrease symptoms, and improve meibomian gland secretion production and quality, with benefits lasting up to six months.

What to Consider When Choosing a Treatment

In our practice at SkyVision Centers, we’ve utilized both LipiFlow and IPL for many years. If a practice already has established thermal/expressive and light-based therapies, adding another modality may not be necessary. However, the data on Tixel is compelling. If starting from scratch, a combination of thermal/expressive and light therapy is a traditional approach. Given the promising results from Dr. Berdy’s team, I would consider Tixel as a strong option.

Darrell E. White, MD, of SkyVision Centers in Westlake, Ohio, can be reached at [email protected].